Seelos Therapeutics, Inc. (SEEL) 10-Q Quarterly Report May 2022

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2022	Apr. 28, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-22245
Entity Registrant Name	SEELOS THERAPEUTICS, INC.
Entity Central Index Key	0001017491
Entity Tax Identification Number	87-0449967
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	300 Park Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	NewYork
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	(646)
Local Phone Number	293-2100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SEEL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		106,090,773

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1017491/000113626122000210/body10-q.htm

View differences made from one quarter to another to evaluate Seelos Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Seelos Therapeutics, Inc..

Continue

Assess how Seelos Therapeutics, Inc.'s management team is paid from their Annual Proxy

Seelos Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

M & A

Other

Filter Subcategory:

All

Income

Product

Expense

Geography

Other

Inside Seelos Therapeutics, Inc.'s 10-Q Quarterly Report:

Financial - Income Highlight
The increase in interest income primarily related to the higher average cash balances during the three months ended March 31, 2022 compared to the three months ended March 31, 2021.

Revenue - Product Highlight
Cash provided by financing activities of $34.3 million during the three months ended March 31, 2021 was due to proceeds from the issuance and sale of common stock, net of costs, of approximately $33.5 million and the proceeds from the exercise of warrants of approximately $5.9 million during the three months ended March 31, 2021.
Financial - Shares Highlight
On May 24, 2021, we completed an underwritten public offering pursuant to which we sold 22,258,066 shares of our common stock at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock.
Financial - Shares Highlight
On January 28, 2021, we completed an underwritten public offering pursuant to which we sold 17,530,488 shares of our common stock at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock.
Financial - Expense Highlight
This decrease in interest expense was due to our repayment of the December 2020 convertible notes during 2021.
Financial - Expense
This increase was primarily due...Read more
M & A - Other
Pursuant to the Vyera Purchase...Read more
Other - Other
We currently have an effective...Read more
Other - Other
Experimental studies suggest ketamine has...Read more
Financial - Expense
G&A expenses increased by $1.5...Read more
Other - Other
19 In addition, although we...Read more
Financial - Expense
Comparison of the Three Months...Read more
Other - Other
Our business model is to...Read more
M & A - Other
We expect to use the...Read more
Other - Other
In consideration for the Final...Read more
Other - Other
Additionally, we are developing several...Read more
Revenue - Product
Liquidity, Capital Resources and Financial...Read more
Other - Other
In March 2020, we began...Read more
Revenue - Geography
We believe there is a...Read more
Other - Other
The accompanying unaudited condensed consolidated...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Seelos Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Certification Of Principal Executive Officer

Exhibit 32.1: Certification Of Chief Executive Officer Pursuant To 18 U.S.C. Section 1350, As

Exhibit 31.2: Certification Of Chief Financial Officer

Exhibit 32.2: Certification Of Chief Financial Officer Pursuant To 18 U.S.C. Section 1350, As

Ticker: SEEL
CIK: 1017491
Form Type: 10-Q Quarterly Report
Accession Number: 0001136261-22-000210
Submitted to the SEC: Tue May 10 2022 4:17:15 PM EST
Accepted by the SEC: Tue May 10 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations